Cellectis Announces Withdrawal of Follow-On Offering
December 15 2020 - 8:15PM
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage
biopharmaceutical company focused on developing immunotherapies
based on gene-edited allogeneic CAR T-cells (UCART), today
announced that it has withdrawn the proposed underwritten offering
of American Depositary Shares (“ADS”) due to market conditions.
The Company believes that it is not in the best
interest of its stockholders to raise the equity capital in the
current market environment. Cellectis remains well capitalized with
a cash position at the end of the third quarter of 2020 of $3081
million to fund its key programs into 2022.
Cellectis is well positioned on all fronts, and
the entire team remains steadfast in its mission to develop
innovative product candidates to benefit cancer patients.
About CellectisCellectis is
developing the first of its kind allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients. As a clinical-stage biopharmaceutical company with
over 20 years of expertise in gene editing, Cellectis is developing
life-changing product candidates utilizing TALEN®, its gene editing
technology, and PulseAgile, its pioneering electroporation system
to harness the power of the immune system in order to target and
eradicate cancer cells.
As part of its commitment to a cure, Cellectis
remains dedicated to its goal of providing life-saving UCART
product candidates to address unmet needs for multiple cancers
including acute myeloid leukemia (AML), B-cell acute lymphoblastic
leukemia (B-ALL) and multiple myeloma (MM).
Cellectis headquarters are in Paris, France,
with additional locations in New York, New York and Raleigh, North
Carolina. Cellectis is listed on the Nasdaq Global Market (ticker:
CLLS) and on Euronext Growth (ticker: ALCLS). For more information,
visit www.cellectis.com.
Follow Cellectis on social media: @cellectis,
LinkedIn and YouTube.
TALEN® is a registered trademark owned by
Cellectis.
For further information, please
contact:
Media contacts:Jennifer Moore,
SVP, Public Relations, 917-580-1088, media@cellectis.comCaitlin
Kasunich, KCSA Strategic Communications, 212-896-1241,
ckasunich@kcsa.com
IR contact:Simon Harnest, SVP,
Corporate Strategy and Finance, 646-385-9008,
simon.harnest@cellectis.com
Disclaimer
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as “at
this time,” “believe,” “expected,” “forward looking”, “promising”
and “will”, or the negative of these and similar expressions. These
forward-looking statements, which are based on our management’s
current expectations and assumptions and on information currently
available to management, include statements These forward-looking
statements are made in light of information currently available to
us and are subject to numerous risks and uncertainties, including
with respect to the duration and severity of the COVID-19 pandemic
and governmental and regulatory measures implemented in response to
the evolving situation. Furthermore, many other important factors,
including those described in our Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2019 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time, as well as
other known and unknown risks and uncertainties may adversely
affect such forward-looking statements and cause our actual
results, performance or achievements to be materially different
from those expressed or implied by the forward-looking statements.
Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
1 Cash position includes cash, cash equivalents and current
financial assets and restricted cash. Restricted cash was $26
million as of September 30, 2020.
PDF available
at: http://ml.globenewswire.com/Resource/Download/1e3ce1d0-8c05-4a4f-a616-c65254c09ee0
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2024 to May 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From May 2023 to May 2024